Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bausch Health Companies Inc (NY: BHC ) 8.080 +0.070 (+0.87%) Official Closing Price Updated: 7:00 PM EDT, Sep 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,851,669 Open 8.050 Bid (Size) 7.980 (5) Ask (Size) 8.080 (1) Prev. Close 8.010 Today's Range 7.930 - 8.110 52wk Range 3.960 - 11.46 Shares Outstanding 358,808,755 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. Via Benzinga Topics Economy Exposures Interest Rates Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues September 16, 2024 Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. Via Benzinga Topics Supply Chain Exposures Supply Chain Performance YTD +3.86% +3.86% 1 Month +35.34% +35.34% 3 Month +18.82% +18.82% 6 Month -18.05% -18.05% 1 Year -2.06% -2.06% More News Read More Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It? September 16, 2024 Via Investor's Business Daily Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens September 04, 2024 Via Benzinga Topics Economy Exposures Interest Rates Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners August 13, 2024 Via ACCESSWIRE Bausch Health Announces Second Quarter 2024 Results July 30, 2024 Via ACCESSWIRE Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings July 29, 2024 Via Benzinga Topics Economy Exposures Interest Rates Bausch Health Responds to Market Rumors July 24, 2024 Via ACCESSWIRE Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock August 02, 2024 Via Benzinga US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? August 01, 2024 Via Benzinga Bausch Health Welcomes Two New Members to the Executive Leadership Team July 19, 2024 Via ACCESSWIRE Bausch Health Announces 2024 Annual Meeting of Shareholder Results May 15, 2024 Via ACCESSWIRE Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November August 01, 2024 Via Benzinga BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy July 24, 2024 Via InvestorPlace Topics Bankruptcy Exposures Financial Legal Why Bausch health Shares Are Falling Today July 24, 2024 Via Benzinga Topics Bankruptcy Exposures Financial Legal Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 24, 2024 Via Benzinga Stocks Plummet After Tech Earnings, Manufacturing Data July 24, 2024 Via Talk Markets Topics Stocks Exposures US Equities Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024 July 11, 2024 Via ACCESSWIRE Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals June 20, 2024 Via ACCESSWIRE Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences June 14, 2024 Via ACCESSWIRE Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults May 23, 2024 Via ACCESSWIRE Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 17, 2024 Via ACCESSWIRE Bausch Health Announces Updates Related to Norwich XIFAXAN Matters May 14, 2024 Via ACCESSWIRE Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin) May 09, 2024 Via ACCESSWIRE Why Bausch Health Companies Stock Dived by More Than 7% Today May 02, 2024 Via The Motley Fool Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
